Twist Bioscience Corporation (TWST) Stock Analysis

Company Overview

Twist Bioscience Corporation functions as a specialized manufacturer and seller of synthetic DNA-based products, leveraging advanced biotechnology to create synthetic genes and gene fragments essential for product development across therapeutics, diagnostics, chemicals, and academic research. The company operates within the Healthcare sector, specifically classified under the Diagnostics & Research industry, positioning it at the intersection of scientific innovation and commercial application. In terms of scale, Twist Bioscience Corporation holds a market capitalization of $2.58B and employs 979 individuals to support its operations. The reported annual revenue of $391.56M combined with a market cap of $2.58B indicates that the market values the company at a significant premium relative to its current book value and sales, suggesting high expectations for future growth despite the current lack of profitability.

Financial Health

The financial performance of Twist Bioscience Corporation for the trailing twelve months reflects a revenue of $391.56M alongside a net income of $-76,583,000 and an EBITDA of $-112,748,000. The substantial gap between the $391.56M in revenue and the negative net income reveals a cost structure where operating expenses significantly exceed gross profit, resulting in a loss that impacts the bottom line more severely than the operating cash generation suggests. Free cash flow stands at $-47,241,876, indicating that the company is currently consuming cash to fund its operations and expansion rather than generating excess liquidity for shareholders or debt repayment. The company's margins tell a complex story, with a gross margin of 51.6% indicating efficient production relative to sales, contrasted sharply by an operating margin of -31.7% and a profit margin of -19.6% which highlight the heavy burden of research, development, and general administrative costs. On the balance sheet, the company holds $197.95M in cash against $113.05M in debt, creating a net cash position, while the debt-to-equity ratio of 24.79 suggests a leveraged capital structure relative to equity, though the absolute debt load is manageable given the cash reserves. Liquidity is robust, evidenced by a current ratio of 3.78, which indicates that the company possesses more than three times the current assets required to cover its short-term liabilities, providing a strong buffer against immediate financial obligations. Furthermore, the return on equity is -16.8% and the return on assets is -13.5%, metrics that reveal management is currently destroying value in terms of shareholder returns and asset utilization due to the ongoing losses required to sustain the business model.

Valuation Assessment

Valuation multiples for Twist Bioscience Corporation present unique characteristics due to its unprofitable status, with a P/E ratio (TTM) of N/A and a forward P/E of -22.32. The absence of a trailing P/E ratio and the negative forward P/E imply that the market cannot value the stock based on current or near-term earnings, as the company is not generating positive earnings to justify a multiple. The price-to-book ratio is 5.65, which indicates that the market is valuing the company at a significant premium over its net asset value, reflecting investor confidence in the intangible value of its intellectual property and future revenue potential rather than current book value. Alternative valuation metrics further illustrate this premium, with a price-to-sales ratio of 6.59 and an EV/EBITDA of -22.12, suggesting that valuation is driven entirely by revenue growth expectations rather than earnings power or cash flow generation. The stock has experienced significant volatility over the past year, trading between a 52-week high of $57.88 and a 52-week low of $23.30. Without the current share price provided in the data, the exact percentage distance from the high or low cannot be calculated, but the range demonstrates a wide trading band of $34.58. The beta of 2.29 indicates that the stock's price is highly sensitive to market movements, exhibiting volatility that is more than twice that of the broader market, which means price swings will likely be amplified during periods of market turbulence.

Growth & Income

Twist Bioscience Corporation is demonstrating strong top-line expansion with a revenue growth of 16.9% year-over-year, while earnings growth is N/A due to the company's continued unprofitability. Because earnings are negative, they are technically growing at a rate that cannot be directly compared to revenue in a positive sense, implying that the company is prioritizing market capture and product development over immediate profitability. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all available capital back into the business to fund synthetic DNA manufacturing capabilities and research initiatives rather than distributing income to shareholders. This growth-focused approach suggests that the company's strategy relies on scaling revenue to eventually achieve the economies of scale necessary to turn the negative operating margin of -31.7% into profitability. The overall growth and income profile is characterized by robust revenue expansion funded by internal cash reserves and external financing, with no reliance on dividend distributions to support shareholder returns.